welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals Awarded Key Patent on HEALER Technology
Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for two Thetis development candidates, TP-252 for familial adenomatous polyposis and TP-452 for dyslipidemia. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids. National filings outside of the United States are underway.
expertly curated content related to this topic
- Douglas L. Riegert-Johnson, MDCurrent Positions: Assistant Professor o...
- Lisa A. North, MSLisa Amacker North is a Genetic Counselo...
- Luca Stocchi, MDLuca Stocchi is a Surgeon and Chair in t...
- Don J. Schiller, MD, Celebrates 25 Years of Surgical SafetyDon J. Schiller, MD, Celebrates 25 Years...
- How Patient Groups have Begun to Influence the Value and Coverage DebateIn 2015, two issues related to medicine ...
- The Effects of Sulindac on the Pathology of Colorectal Remnant Polyps of Familial Adenomatous Polyposis (FAP) Patien...OBJECTIVE : To evaluate the long-term ef...
- Victor L. Fox, MDCurrent Positions: Director, Gastrointes...
English
Portuguese
Spanish